LY 156735

Drug Profile

LY 156735

Alternative Names: LY156,735; PD 6735; TIK-301

Latest Information Update: 26 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Tikvah Therapeutics
  • Class Sleep disorder therapies; Small molecules; Tryptamines
  • Mechanism of Action Melatonin receptor agonists; Serotonin 2C receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Sleep disorders

Most Recent Events

  • 25 Nov 2005 Data presented at the 18th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2005) have been added to the adverse events and Anxiety disorders therapeutic trials sections
  • 28 May 2004 LY 156735 has received orphan drug status for the treatment of circadian sleep disorders in totally blind individuals in the US
  • 24 May 2004 Data from a media release have been added to the Anxiety disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top